These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26808834)

  • 1. Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia.
    Ji S; Li A; Wu K; Deng C; Dong F; Li L; Zhou T; Yue W; Wang CY; Lu W
    Pharmacopsychiatry; 2016 May; 49(3):117-23. PubMed ID: 26808834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia.
    Østergaard SD; Lemming OM; Mors O; Correll CU; Bech P
    Acta Psychiatr Scand; 2016 Jun; 133(6):436-44. PubMed ID: 26558537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial.
    Glick HA; Li P; Harvey PD
    Schizophr Res; 2015 Aug; 166(1-3):110-4. PubMed ID: 26044113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment effectiveness in patients with schizophrenia as measured by the ASSESS battery - first longitudinal data.
    Ladea M; Barbu CM; Juckel G
    Psychiatr Danub; 2015 Dec; 27(4):364-70. PubMed ID: 26609648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief PANSS to assess and monitor the overall severity of schizophrenia.
    Yamamoto N; Inada T; Shimodera S; Morokuma I; Furukawa TA
    Psychiatry Clin Neurosci; 2010 Jun; 64(3):262-7. PubMed ID: 20602726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An excitement subscale of the Positive and Negative Syndrome Scale.
    Lindenmayer JP; Brown E; Baker RW; Schuh LM; Shao L; Tohen M; Ahmed S; Stauffer VL
    Schizophr Res; 2004 Jun; 68(2-3):331-7. PubMed ID: 15099614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.
    Pilla Reddy V; Kozielska M; Johnson M; Suleiman AA; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Clin Pharmacokinet; 2012 Apr; 51(4):261-75. PubMed ID: 22420580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equipercentile linking of the BPRS and the PANSS.
    Leucht S; Rothe P; Davis JM; Engel RR
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
    JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the Positive and Negative Syndrome Scale (PANSS).
    Khan A; Yavorsky WC; Liechti S; DiClemente G; Rothman B; Opler M; DeFries A; Jovic S
    J Clin Psychopharmacol; 2013 Feb; 33(1):109-17. PubMed ID: 23277234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.
    Masand P; O'Gorman C; Mandel FS
    Schizophr Res; 2011 Mar; 126(1-3):174-83. PubMed ID: 21185155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia.
    Kozielska M; Pilla Reddy V; Johnson M; de Ridder F; Vermeulen A; Liu J; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):53-8. PubMed ID: 23434198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode.
    Peuskens J; Kaufman L; Van Vleymen B
    Schizophr Res; 2007 Sep; 95(1-3):169-73. PubMed ID: 17630255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: the use of PANSS total score and clinical utility.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):144-52. PubMed ID: 23473810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia.
    Lin CH; Lin HS; Lin SC; Kuo CC; Wang FC; Huang YH
    Acta Psychiatr Scand; 2018 Feb; 137(2):98-108. PubMed ID: 29280500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.